August 15, 2022

Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

– Phase II acute pain program to initiate in September – Ended quarter with $50 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (August 15, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfideplatform to develop next-generation safer therapies that target … Continued

more
June 30, 2022

Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights

– Phase II acute pain program to initiate in early calendar Q4 2022 – Ended year with $55 million in cash and equivalents, providing over two years of runway TORONTO, CANADA — (June 30, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation … Continued

more
June 15, 2022

Antibe Therapeutics Announces Amendment to Warrant Terms

TORONTO, CANADA — (June 15, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company”), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “Warrant Extension”) and amending the exercise price (the “Amended Exercise Price”) of 3,117,957 … Continued

more
May 25, 2022

Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs

TORONTO, CANADA — (May 25, 2022) — Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The … Continued

more
May 2, 2022

Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary

– $6.5 million all-cash transaction, including milestone payments – Enables exclusive focus on drug pipeline TORONTO, CANADA — (May 2, 2022) — Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the signing of a binding … Continued

more
April 25, 2022

Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, CANADA — (April 25, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference being held in person on May 2-3, 2022. Dan Legault, Antibe’s … Continued

more
February 14, 2022

Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results

– Acute pain clinical program for otenaproxesul initiating this quarter – Ended quarter with a $59 million cash position TORONTO, CANADA — (February 14, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and … Continued

more

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK